- Raised funding round, Oct 2017
About
ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company focused on developing a pipeline of disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBCs novel approach to the treatment of neurodegeneration is based on years of innovative scientific discoveries made by Prof. Michal Schwartz of the Weizmann Institute of Science. IBCs lead programs are being developed for the treatment of Alzheimers disease, employing a novel approach of blocking the PD-1/PD-L1 immune checkpoint pathway. In June 2017, Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, obtained the rights to IBCs research into treatment for Alzheimers disease. As part of the agreement, Lundbeck will provide the funding for, as well as participate in, additional research that will allow the identification of potential therapies for clinical trials. Lundbeck also obtained minority ownership of IBC and has the exclusive option to take over the rights and activities relating to this technology at a later date.
Funding history · 1 round · — total
Q&A
- What is ImmunoBrain Checkpoint's primary focus?
- ImmunoBrain Checkpoint is a biopharmaceutical company focused on developing disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways.
- What is ImmunoBrain Checkpoint's lead program targeting?
- ImmunoBrain Checkpoint's lead programs are being developed for the treatment of Alzheimer's disease, utilizing an approach of blocking the PD-1/PD-L1 immune checkpoint pathway.
- When was ImmunoBrain Checkpoint founded?
- ImmunoBrain Checkpoint was founded in February 2015.
- How many employees does ImmunoBrain Checkpoint have?
- ImmunoBrain Checkpoint has 19 employees, falling within the 11-50 employee bucket.
- What was a significant partnership for ImmunoBrain Checkpoint in 2017?
- In June 2017, Lundbeck, a global pharmaceutical company, obtained the rights to ImmunoBrain Checkpoint's research into Alzheimer's disease treatment. Lundbeck also provides funding for additional research and holds minority ownership with an exclusive option to take over the technology rights.
- Which investor participated in ImmunoBrain Checkpoint's funding round in October 2017?
- SBI JI Innovation Fund participated in ImmunoBrain Checkpoint's funding round in October 2017.
- What is ImmunoBrain Checkpoint's current funding stage?
- ImmunoBrain Checkpoint is currently in the Seed funding stage.
- Where is ImmunoBrain Checkpoint's headquarters located?
- ImmunoBrain Checkpoint's headquarters is located in Ness Ziona, Center District, Israel.
Team · 1
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | immunobrain.com/ |
|---|---|
| linkedin.com/company/10319109 |
Identifiers & details
| Founded | 2015-2 |
|---|---|
| Employees (exact) | 19 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Publications (Crossref)
| Works | 1 |
|---|
Web history (Wayback)
| Domain | immunobrain.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|